Last reviewed · How we verify
NCT03893591
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity
trial testing Anti Xa levels in Anticoagulant in 82 participants. Completed in 29 February 2020.
29 February 2020
Quick facts
| Lead sponsor | HaEmek Medical Center, Israel |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 82 |
| Start date | 6 May 2019 |
| Primary completion | 29 February 2020 |
| Estimated completion | 29 February 2020 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Anti Xa levels
Conditions studied
- Anticoagulant — all drugs for Anticoagulant →
- Apixaban — all drugs for Apixaban →
- Obesity — all drugs for Obesity →
Sponsor
HaEmek Medical Center, Israel
Who can join
18 and older, any sex, with Anticoagulant or Apixaban. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
The Influence of High Body Mass Index (BMI > 35 kg/m<sup>2</sup>) on Apixaban Plasma Concentration in Patients with Atrial Fibrillation.
Hilu M, Issawy M, Colodner R, Eitam H, et al · · 2025 · PMID 39424747 · DOI 10.1007/s40256-024-00678-w
Verify or expand the search:
- PubMed search for NCT03893591
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anticoagulant
Currently open trials in the same condition.
- NCT04257487 — Sulodexide, VESSEL®, for the Prevention of Recurrent Venous Thromboembolism (The Jason Study) · Phase 3 · recruiting
- NCT04010955 — Adding Antiplatelet During Edoxaban Treatment in Stroke Patients With Non-valvular Atrial Fibrillation (ADD-ON) · active not recruiting
Other HaEmek Medical Center, Israel trials
Trials by the same sponsor.
- NCT06656286 — Hysteroscopic Intrauterine Suturing · NA · not yet recruiting
- NCT06803992 — Induction of Labor - Comparison Propess With Prostaglandin E2 Vaginal Gel and Balloon Catheter · Phase 4 · recruiting
- NCT06542367 — Trans Canal Tympanoplasty With Local Anesthesia Using Fat Graft and "TachoSil" · NA · not yet recruiting
- NCT05732155 — Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. · Phase 2 · unknown
- NCT05933018 — Night Hyperglycemia and Fatty Liver in Type 1 Diabetes · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03893591 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by HaEmek Medical Center, Israel
- Last refreshed: 1 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03893591.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing